Share on StockTwits

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Henry Morgan sold 2,060 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $27.01, for a total value of $55,640.60. Following the completion of the sale, the director now directly owns 35,133 shares of the company’s stock, valued at approximately $948,942. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded down 0.04% on Tuesday, hitting $26.98. The stock had a trading volume of 19,943 shares. BioSpecifics Technologies Corp. has a 1-year low of $15.55 and a 1-year high of $27.89. The stock has a 50-day moving average of $25.15 and a 200-day moving average of $23.92. The company has a market cap of $172.5 million and a price-to-earnings ratio of 39.75.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) last released its earnings data on Thursday, May 8th. The company reported $0.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.07 by $0.05. The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $2.46 million. Analysts expect that BioSpecifics Technologies Corp. will post $0.63 EPS for the current fiscal year.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.